Corvus Advances Soquelitinib Into Phase 2 Eczema Trial: What Investors Should Watch

Corvus Pharmaceuticals Inc. (CRVS) announced an update on their ongoing clinical study.

The Phase 2 SIERRA1 study, officially titled “A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (AD),” aims to see if Corvus Pharmaceuticals’ oral drug can safely reduce AD symptoms versus placebo in adults with harder-to-treat disease.

The trial tests soquelitinib (also known as CPI-818), an oral tablet designed to calm immune activity that drives eczema flares. Participants receive different doses of soquelitinib or a look‑alike placebo pill to see which regimen best balances benefit and side effects over a 12‑week treatment window.

This is an interventional Phase 2 study where patients are randomly assigned to one of several treatment groups or placebo. The trial is double‑blind and placebo‑controlled, meaning neither patients nor study staff know who gets the active drug, and the main aim is to test whether soquelitinib can safely improve disease compared with placebo.

According to the listing, the study was first submitted on Feb. 23, 2026, marking the formal start of trial setup. The last update was posted on Mar. 3, 2026, confirming that the study remains in the recruiting phase and that the protocol has been recently reviewed.

While exact primary and final completion dates are not listed, the 12‑week treatment plus follow‑up suggests key efficacy and safety data could emerge within roughly a year of full enrollment. For investors, this timeline sets expectations for when the next major readouts might hit and potentially move the stock.

This update signals that Corvus is advancing soquelitinib into a large, competitive eczema market currently led by biologics like dupilumab and oral JAK inhibitors. Early positive signals could lift CRVS by supporting a differentiated oral option, while setbacks or safety issues may weigh on sentiment given the crowded field and high bar for new entrants.

Investors should also watch how the broader dermatology and immunology group trades around AD data, as peers’ readouts often reset expectations for efficacy and safety. The SIERRA1 study is currently recruiting and recently updated, with more details and ongoing changes available on the ClinicalTrials.gov portal.

To learn more about CRVS’s potential, visit the Corvus Pharmaceuticals Inc. drug pipeline page.